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Background
Treatment of chronic idiopathic urticaria (CIU) can be
difficult with antihistamines only and therefore we
assessed (1) efficacy ofmontelukast as add-on therapy,
and (2) if any clinical features or laboratory markers
were associated with a response to montelukast.
Methods
Patients who received montelukast for CIU between
2008-2011 (4-year period) were retrospectively identified
from clinic letters. Clinical features of duration of urti-
caria, medication use, autoimmunity and laboratory
investigations that included basopenia and mean platelet
volume on full blood count, complement levels, specific
IgE, autoimmune serology [antinuclear antibody (ANA),
thyroid peroxidase antibodies, serum histamine releasing
antibody (using donor basophils, positive >18.5%)] were
collected and analysed. The primary end point was ade-
quate control of urticaria without additional therapy.
Patients with features of urticarial vasculitis and those
who required corticosteroids or immunosuppressants
were excluded. Nonparametric statistical data were cal-
culated using GraphPad Prism software.
Results
28 patients (11 males, 17 females; age mean±SD 36.5±15.4
years) received montelukast and the average duration of
urticaria was 3.5 years. Six patients had autoimmunity (5
diabetes, 1 hypothyroidism). 24 patients (86%) were on
anti-H1 (cetirizine 10mg/fexofenadine 180mg) and anti-
H2 blockers (ranitidine 150mg) when montelukast was
started. 13 patients (46.4%) responded to montelukast; the
mean±SD age 31±13.98 years of 9 males and 4 females
(age mean±SD 35±14.99 years) who responded was non-
significant (2-sided unpaired t test p value 0.6498).
Duration of anti-H1 use (<1 year vs >1 year) between
males/females and response to montelukast was also non-
significant (p value 0.4887). One patient responded to
montelukast and fexofenadine only. Two patients required
short course of steroids for urticarial flare while on monte-
lukast. 9 patients continue to remain on montelukast. 17
patients had basopenia, 9 high mean platelet volumes, 2
had positive ANA, 4 positive specific IgE, C3/C4 levels
tested in all 23 patients were normal, 4 had positive hista-
mine release antibody test and 3 with thyroid peroxidase
antibodies. 6 patients had montelukast related side effects:
nausea (1), dyspepsia (1), depression (1) and worsening
urticaria (3).
Conclusions
Montelukast as add-on therapy with anti-H1/anti-H2
blockers was effective in almost half of patients with
CIU. No clinical features or laboratory markers were
associated with response to montelukast.
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